In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endo strengthens pain portfolio through Penwest acquisition

Executive Summary

Several months after acquiring Medical Enterprises Europe BV and HealthTronics to diverse its portfolio into medical devices, Endo Pharmaceuticals Holdings Inc. (branded and generic products) is back into pharma dealmaking again, spending $159.7mm for Penwest Pharmaceuticals Co., a public company specializing in extended-release drug delivery. Endo will pay $5 (a 39% premium) for each of Penwest's 32mm shares outstanding.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies